Skip to main content
Daniel Oliver

Daniel Oliver

American editor

Sep 1, 2026

12:32
So let's chat about it.
12:34
Yeah, so look, there's some interesting questions when you're tackling something as large as aging.
12:38
One of them is how do you get an aging therapeutic approved, right? And there's kind of a couple of issues with it.
12:45
You can imagine, okay, we're going to run a study and we're going to see how long people live.
12:48
Well, it turns out that takes a really long time to do and is not very capital efficient.
12:54
And so while that's actually doable through the FDA, you just don't see people really do that.
12:59
The next thing people kind of come to is like, oh, are there surrogate biomarkers that you can read? And the answer is kind of yes.
16:34
And then what's the timeline for the human?
MattHOST
0:21
Is it neuro- is anecdote neurotransgressive? Is anecdote-
0:25
I think I say...
0:27
So I think where that came from was originally that that's about, not really about the academic visit, about the access rider bit.
0:35
So the, when you ask to do an access rider, you're obviously meant to talk in quite practical and direct ways about what your needs are.
0:45
And so when I was doing my, writing my access rider, I kept, like, going, trying to go like, "Oh, let me give you an example." You know, like, so I kept slipping into anecdotes, and I just thought, "I'm just gonna write my access rider as a series of these anecdotes." And then also, like, the way that they're made, those anecdotes don't really work always to actually exemplify.
1:08
Always so what-- I've always found, like, the examples in such of like a betrayal of the actual thing you're trying to get across.

9 MINS LATER

MattHOST
10:06
I don't know.
10:08
I find there's something about...

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.